Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031694 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
A Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00031694: Completed Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
NCT00031694 is a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031694, a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin-1 may help paclitaxel kill more cancer cells by making tumor cells more sensitive to the drug.
Primary Outcome
Number of participants with a Response rate of at least 30%. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST).
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG bryostatin 1
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2002-03 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00031694 record still lists
NCT00031694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (76% lower).
The record links to 5 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00031694 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00031694 about?
NCT00031694 is a clinical study titled "Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer". Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin-1 ma...
What is the current status of trial NCT00031694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2002-03. Estimated completion is 2010-04.
What conditions does trial NCT00031694 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Cancer, Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT00031694?
The interventions under investigation include: paclitaxel (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00031694?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031694 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00031694's enrollment target sits among peer trials
19 13th of 15 higher than 3 of 15 other Stage IV Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia